These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36740042)

  • 1. Atorvastatin downregulates plasma procarboxypeptidase U concentrations and improves fibrinolytic potential dose-dependently in hyperlipidemic individuals.
    Claesen K; Sim Y; Basir S; De Belder S; van den Keybus T; Van Edom G; Stoffelen H; De Keulenaer GW; Bosmans J; Bringmans T; De Meester I; Hendriks D
    J Thromb Haemost; 2023 May; 21(5):1266-1273. PubMed ID: 36740042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study.
    Claesen K; Mertens JC; Basir S; De Belder S; Maes J; Bosmans J; Stoffelen H; De Meester I; Hendriks D
    Clin Ther; 2021 May; 43(5):908-916. PubMed ID: 33910760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic Effects of Atorvastatin Result in a Downregulation of the Carboxypeptidase U System (CPU, TAFIa, CPB2) in a Mouse Model of Advanced Atherosclerosis.
    Claesen K; Roth L; Mertens JC; Hermans K; Sim Y; Hendriks D
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34684024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis.
    Mertens JC; Claesen K; Leenaerts D; Sim Y; Lambeir AM; Hendriks D
    J Thromb Haemost; 2019 Jun; 17(6):878-884. PubMed ID: 30887647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.
    Leenaerts D; Aernouts J; Van Der Veken P; Sim Y; Lambeir AM; Hendriks D
    Thromb Haemost; 2017 Jul; 117(8):1498-1508. PubMed ID: 28692110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.
    Silveira A; Schatteman K; Goossens F; Moor E; Scharpé S; Strömqvist M; Hendriks D; Hamsten A
    Thromb Haemost; 2000 Sep; 84(3):364-8. PubMed ID: 11019956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?
    Claesen K; Mertens JC; Leenaerts D; Hendriks D
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction.
    Mertens JC; Leenaerts D; Brouns R; Engelborghs S; Ieven M; De Deyn PP; Lambeir AM; Hendriks D
    J Thromb Haemost; 2018 Feb; 16(2):342-348. PubMed ID: 29194929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models.
    Leenaerts D; Loyau S; Mertens JC; Boisseau W; Michel JB; Lambeir AM; Jandrot-Perrus M; Hendriks D
    J Thromb Haemost; 2018 Oct; 16(10):2057-2069. PubMed ID: 30053349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients.
    Brouns R; Heylen E; Sheorajpanday R; Willemse JL; Kunnen J; De Surgeloose D; Hendriks DF; De Deyn PP
    Clin Neurol Neurosurg; 2009 Feb; 111(2):165-70. PubMed ID: 18980797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma.
    Leurs J; Wissing BM; Nerme V; Schatteman K; Björquist P; Hendriks D
    Thromb Haemost; 2003 Feb; 89(2):264-71. PubMed ID: 12574805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma.
    Schatteman KA; Goossens FJ; Scharpé SS; Neels HM; Hendriks DF
    Clin Chem; 1999 Jun; 45(6 Pt 1):807-13. PubMed ID: 10351989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis.
    Schatteman KA; Goossens FJ; Scharpé SS; Hendriks DF
    Thromb Haemost; 1999 Dec; 82(6):1718-21. PubMed ID: 10613660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
    Atalar E; Ozmen F; Haznedaroglu I; Açil T; Ozer N; Ovünç K; Aksöyek S; Kes S
    Int J Cardiol; 2002 Aug; 84(2-3):227-31. PubMed ID: 12127376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.
    Leenaerts D; Bosmans JM; van der Veken P; Sim Y; Lambeir AM; Hendriks D
    J Thromb Haemost; 2015 Dec; 13(12):2227-32. PubMed ID: 26340515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge.
    Willemse JL; Hendriks DF
    Clin Chem; 2006 Jan; 52(1):30-6. PubMed ID: 16299049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
    Orem C; Uydu HA; Yilmaz R; Gökçe M; Baykan M; Eminagaoglu S; Orem A
    Jpn Heart J; 2004 Nov; 45(6):977-87. PubMed ID: 15655273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis.
    Claesen K; Sim Y; Bracke A; De Bruyn M; De Hert E; Vliegen G; Hotterbeekx A; Vujkovic A; van Petersen L; De Winter FHR; Brosius I; Theunissen C; van Ierssel S; van Frankenhuijsen M; Vlieghe E; Vercauteren K; Kumar-Singh S; De Meester I; Hendriks D
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procarboxypeptidase U (TAFI) and the Thr325Ile proCPU polymorphism in patients with hereditary mucocutaneous hemorrhages.
    Matus V; Willemse J; Quiroga T; Goycoolea M; Aranda E; Panes O; Pereira J; Hendriks D; Mezzano D
    Clin Chim Acta; 2009 Mar; 401(1-2):158-61. PubMed ID: 19038242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ProCPU Is Expressed by (Primary) Human Monocytes and Macrophages and Expression Differs between States of Differentiation and Activation.
    Claesen K; De Loose J; Van Wielendaele P; De Bruyn E; Sim Y; Thys S; De Meester I; Hendriks D
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.